Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Lung Cancer Highlights, 2011 by Dr. Weiss, Part 2: ALK and other New Molecular Targets
Author
Howard (Jack) West, MD

Here is the second part of the presentation on "Lung Cancer Highlights, 2011" by Dr. Jared Weiss.  This section of his talk focuses on the striking story of the identification of the ALK rearrangement as a relevant target in lung cancer, along with an impressive treatment for this subgroup, and other new targets, such as ROS-1.  

Below you'll find the audio and video versions of the podcast, as well as the transcript and figures.

Dr. Weiss Lung Cancer Highlights 2011, Pt 2 ALK and New Molecular Targets Audio Podcast

Dr. Weiss Lung Cancer  Highlights 2011, Pt 2 ALK and New Molecular Targets Transcript

Dr. Weiss Lung Cancer Highlights 2011 Pt 2 ALK and New Molecular Targets Figs

The third and final part of Dr. Weiss's presentation will focus on advances for broader populations: smokers and the elderly.  He'll cover the lung cancer screening trial known as the NLST, as well as an influential presentation of single agent vs. doublet chemotherapy in elderly patients with advanced NSCLC.  Look for that here very soon.

Thanks again to LUNGevity Foundation for their sponsorship of this work with us, making this content possible.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora